跳至主要内容
临床试验/NCT00594035
NCT00594035已完成不适用

A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery

Integra LifeSciences Corporation2 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2005年9月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
158
试验地点
2
主要终点
Watertight Dural Closure

研究概览

简要总结

To evaluate the safety and efficacy of the Spinal Sealant as an adjunct to sutured dural repair compared with standard of care methods (control) to obtain watertight dural closure in patients undergoing spinal surgery.

详细描述

Neurosurgical procedures in the spine often involve incision of the dura mater to access the spinal cord. If the dural incision is not properly repaired and watertight closure is not achieved cerebrospinal fluid (CSF) can escape presenting a risk for significant morbidity. The most frequent complication of CSF leak is recurring headache complicated with symptoms of nausea and vomiting. Furthermore fluid collection under skin prevents proper wound healing and may lead to wound breakdown and infection of the incision or both. Persistent CSF leak has also been associated with the development of cerebellar hemorrhage and subdural hematoma. Primary repair and watertight closure are paramount to minimizing risk and sequelae associated with CSF leak.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are scheduled for an elective spinal procedure that requires a dural incision will be considered for study participation.
  • Patient requires a procedure that involving surgical wound classification Class 1/Clean (per CDC criteria)
  • Presence of a non-watertight dural closure, either spontaneously or upon Valsala maneuver at 20-25 cm H20 for 5-10 seconds.

排除标准

  • Active spinal and/or systemic infection
  • Patient requires additional spinal surgery within the study time period
  • Patient has had a previous spinal surgery involving dural exposure and/or entry at the same level(s) as the study procedure
  • Patient has a pre-existing external lumbar CSF drain or internal CSF shunt
  • Patient is participating in a clinical trial of another investigational device or drug
  • Patient with creatinine > 2.0 mg/dL
  • Patient with total bilirubin > 2.5 mg/dL
  • Pregnant or breast-feeding females or females who wish to become pregnant during the length of study participation
  • Patient has been treated with chronic steroid therapy (>4 weeks) unless discontinued more than 6 weeks prior to surgery
  • Patient has documented history or significant coagulopathy with a PTT >35 sec, PT/INR >1.2, receiving asprin, or NSAIDS at the time of surgery
  • Patient receiving warfarin or heparin at the time of surgery
  • Patient has a diagnosed and documented compromised immune system and/or autoimmune disease
  • Patient has has chemotherapy treatment within 6 months prior to, or planned during the study
  • Patient has had prior radiation treatment to the surgical site or has planned radiation therapy within 30 days post procedure
  • Patient has known malignancy or other condition with prognosis shorter than 6 months
  • Patients with documented history of uncontrolled diabetes
  • Patient requires use of synthetic or non-autologous duraplasty material
  • Patient has a gap greater than 2mm remaining after primary dural closure
  • Patient has undergone laminoplasty decompression
  • Patient has undergone a syringomyelia procedure where the shunt is not placed in the subarachnoid position
  • Patient has undergone a Chiari Malformation procedure that does not entail a dural incision at or below the C1 level
  • The investigator determines that participation in the study may jeopardize the safety or welfare of the patient
  • The investigator determines that the patient should not be included in the study for reason(s) not already specified

研究组 & 干预措施

1

Experimental

Spinal Sealant

干预措施: Spinal Sealant System (Device)

2

Active Comparator

Standard of care

干预措施: Standard of care (Device)

结局指标

主要结局

Watertight Dural Closure

时间窗: Intra-Operative

Number of subjects displaying a watertight dural closure after assigned treatment intra-operatively.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验